Georgios Paslakis

Summary

Affiliation: Central Institute of Mental Health
Country: Germany

Publications

  1. ncbi Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment
    Georgios Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, J5, 68159 Mannheim, Germany
    J Psychiatr Res 44:556-60. 2010
  2. ncbi The effect of treatment with ketoconazole on central CRH systems of depressed patients
    Georgios Paslakis
    Central Institute of Mental Health, Mannheim, Germany
    Hum Psychopharmacol 26:35-40. 2011
  3. doi Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression
    G Paslakis
    Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
    Med Hypotheses 79:222-5. 2012
  4. doi The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study
    G Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany
    Pharmacopsychiatry 45:96-9. 2012
  5. doi Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression
    Georgios Paslakis
    Central Institute of Mental Health, Mannheim, Germany
    J Psychopharmacol 25:1344-6. 2011
  6. doi [Epigenetic mechanisms in major depression]
    G Paslakis
    Klinik fur Psychiatrie und Psychotherapie, Zentralinstitut fur Seelische Gesundheit, Mannheim, Universitat Heidelberg, Mannheim, Deutschland
    Nervenarzt 82:1431-2, 1434-8. 2011
  7. doi [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data]
    G Paslakis
    Klinik fur Psychiatrie und Psychotherapie, Zentralinstitut fur Seelische Gesundheit, Mannheim
    Fortschr Neurol Psychiatr 79:204-12. 2011
  8. doi The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients
    Georgios Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, J5, 68159, Mannheim, Germany
    Eur Arch Psychiatry Clin Neurosci 261:173-7. 2011
  9. doi Discrimination between patients with melancholic depression and healthy controls: comparison between 24-h cortisol profiles, the DST and the Dex/CRH test
    Georgios Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany
    Psychoneuroendocrinology 36:691-8. 2011
  10. doi A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine
    Georgios Paslakis
    Central Institute of Mental Health, J5, 68159 Mannheim, Germany
    J Psychiatr Res 44:1154-7. 2010

Detail Information

Publications16

  1. ncbi Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment
    Georgios Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, J5, 68159 Mannheim, Germany
    J Psychiatr Res 44:556-60. 2010
    ....
  2. ncbi The effect of treatment with ketoconazole on central CRH systems of depressed patients
    Georgios Paslakis
    Central Institute of Mental Health, Mannheim, Germany
    Hum Psychopharmacol 26:35-40. 2011
    ..Steroid-synthesis inhibitors are reported to reduce psychopathology in treatment-resistant depressed patients...
  3. doi Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression
    G Paslakis
    Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
    Med Hypotheses 79:222-5. 2012
    ..g. possible peripheral side effects) while directly targeting central nervous circuitries, the clinical intranasal administration of IGF-I appears to be a plausible and promising treatment option of depression...
  4. doi The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study
    G Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany
    Pharmacopsychiatry 45:96-9. 2012
    ..Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n = 7) or risperidone (n = 7)...
  5. doi Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression
    Georgios Paslakis
    Central Institute of Mental Health, Mannheim, Germany
    J Psychopharmacol 25:1344-6. 2011
    ..Our results suggest that antidepressant treatment with paroxetine might contribute to a decrease in vascular mortality risk irrespective of treatment outcome...
  6. doi [Epigenetic mechanisms in major depression]
    G Paslakis
    Klinik fur Psychiatrie und Psychotherapie, Zentralinstitut fur Seelische Gesundheit, Mannheim, Universitat Heidelberg, Mannheim, Deutschland
    Nervenarzt 82:1431-2, 1434-8. 2011
    ..These are acquired modifications that can be partially reversed by drug treatment (antidepressants)...
  7. doi [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data]
    G Paslakis
    Klinik fur Psychiatrie und Psychotherapie, Zentralinstitut fur Seelische Gesundheit, Mannheim
    Fortschr Neurol Psychiatr 79:204-12. 2011
    ..g., ketamine] have shown antidepressant properties in mostly preclinical and some clinical trials. Further substances are currently being investigated. This review provides an insight into the newest developments in this field...
  8. doi The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients
    Georgios Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, J5, 68159, Mannheim, Germany
    Eur Arch Psychiatry Clin Neurosci 261:173-7. 2011
    ..Due to the preliminary character of the present investigation, no conclusions about the clinical efficacy of reboxetine can be drawn...
  9. doi Discrimination between patients with melancholic depression and healthy controls: comparison between 24-h cortisol profiles, the DST and the Dex/CRH test
    Georgios Paslakis
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany
    Psychoneuroendocrinology 36:691-8. 2011
    ..3%). The assessment of cortisol in plasma is an easy to perform, cost-saving method for the evaluation of the HPA system activity, which may have a series of clinical and scientific implications for the depressive disorder...
  10. doi A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine
    Georgios Paslakis
    Central Institute of Mental Health, J5, 68159 Mannheim, Germany
    J Psychiatr Res 44:1154-7. 2010
    ..The DEX/CRH test has been proposed to be suitable as a biomarker for the prediction of treatment response in depression...
  11. ncbi The putative role of human peritoneal adipocytes in the fight against bacteria: synthesis of the antimicrobial active peptide DEFA1-3
    Georgios Paslakis
    Institut für Klinische Biochemie der Medizinischen Poliklinik, University of Munich, Munich, Germany
    Nephron Exp Nephrol 115:e96-100. 2010
    ..As defensins are natural antimicrobial peptides, we hypothesized that adipocytes as the major constituents of the omentum could play an important role in protecting against infection by generating defensin (DEFA1-3)...
  12. doi [Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?]
    G Paslakis
    Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut fur Seelische Gesundheit Mannheim, Universitat Heidelberg, J5, 68159, Mannheim
    Nervenarzt 81:277-88. 2010
    ....
  13. doi A cross-over study of effects on the hypothalamus-pituitary-adrenal (HPA) axis and the sympathoadrenergic system in magnetic field strength exposure from 0 to 7 T
    Maria Gilles
    Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, J5, Medical Faculty Mannheim, Heidelberg University, Germany
    Stress 16:172-80. 2013
    ..Our study suggests that the results of MRI studies using stress-paradigms are not influenced by the static magnetic field itself...
  14. doi Visceral and subcutaneous fat in patients treated with olanzapine: a case series
    Maria Gilles
    Department of Psychiatry and Psychotherapy, and Neuroradiology, Central Institute of Mental Health, Mannheim, Germany
    Clin Neuropharmacol 33:248-9. 2010
    ..We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome...
  15. ncbi Intrauterine exposure to cigarette smoke is associated with increased ghrelin concentrations in adulthood
    Georgios Paslakis
    Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
    Neuroendocrinology 99:123-9. 2014
    ..Animal studies have also shown that intrauterine programming of orexigenic systems persists even until adolescence/adulthood...
  16. doi Cognition and sensation in very high static magnetic fields: a randomized case-crossover study with different field strengths
    Angela Heinrich
    Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Square J5, D 68159 Mannheim, Germany
    Radiology 266:236-45. 2013
    ..To establish the extent to which representative cognitive functions in subjects undergoing magnetic resonance (MR) imaging are acutely impaired by static magnetic fields of varying field strengths...